Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 9;29(1):104–114. doi: 10.1038/s41591-022-02128-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a, Swimmer’s plot of patient response over time in the mITT population (N = 38). The inset is response over time in patients with SS (n = 16). b, DoR profiles show the change from baseline in target lesions using RECIST version 1.1 in the overall treatment group after first infusion for responders and non-responders. The inset shows the change from baseline in target lesions in patients with SS. The probability of DoR was 100% (95% CI: 100, 100) at ≥12 weeks and 60% (95% CI: 20.4, 80.5) at ≥24 weeks. Duration of stable disease probability at ≥24 weeks for patients with SS was 50% (95% CI: 22.5%, 75.0%). c, Kaplan–Meier curves show PFS in the mITT population. The inset shows the PFS curve for the patients with SS. The median PFS for the mITT population was 12.3 weeks (95% CI: 10.9, 19.1) and 20.4 weeks (95% CI: 10.0, 52.1) for the patients with SS. PFS events in the mITT population included 25 events (65.8%) of PD and four events (10.5%) of death. PFS probability was 60% (95% CI: 44.8, 76.6) at 12 weeks and 30% (95% CI: 14.1, 45.2) at 24 weeks. PFS probability in the patients with SS was 70% (95% CI: 0.44, 0.89) at 12 weeks and 50% (95% CI: 0.19, 0.68) at 24 weeks. d, Kaplan–Meier curves show OS in the mITT population. The inset shows the OS for patients with SS. The median OS for the mITT population was 42.9 weeks (95% CI: 20.7, not reached) and 58.1 weeks (95% CI: 36.3, not reached) for patients with SS. OS probability was 90% (95% CI: 69.8, 94.0) at 12 weeks and 70% (95% CI: 49.6, 82.1) at 24 weeks. OS probability in patients with SS was 90% (95% CI: 0.63, 0.99) at 12 weeks and remained 90% (95% CI: 0.59, 0.97) at 24 weeks.